Results 91 to 100 of about 117,898 (292)
Proteomes, 2014 Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases.
Katerina Arvaniti +5 more
doaj +1 more source
, 2018 Anorectal melanoma (AM) is a rare malignancy, characterized by aggressive behavior and a poor prognosis. AM is more frequent in female patients aged over 50 years.
Dario Didona +4 more
core +1 more source
CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 583-595, March 2025.ABSTRACT Prior pharmacokinetic (PK) analysis revealed that increased alpha‐1‐acid glycoprotein (AAG) levels are associated with decreased imatinib unbound fraction in coronavirus disease 2019 (COVID‐19) patients. This study aimed to investigate the PK of total and unbound concentrations of imatinib and the metabolite N‐desmethyl imatinib in ...
Medhat M. Said +10 more
wiley +1 more source
The potential role of mitochondrial impairment in the pathogenesis of imatinib-induced renal injury
Heliyon, 2019 Imatinib is a tyrosine kinase inhibitor widely administered against chronic myeloid leukemia. On the other hand, drug-induced kidney proximal tubular injury, electrolytes disturbances, and renal failure is a clinical complication associated with imatinib
Ehsan Emadi +8 more
doaj +1 more source
Allergy, EarlyView.This study investigates the effect of IL‐33 and Hymenoptera venom on mast cell cytokine profiles under venom immunotherapy (VIT)‐like conditions. Our in vitro model of VIT‐like mast cell stimulation demonstrates a modulatory effect of IL‐33 on the secreted mast cell cytokine profile.
Andrea R. Teufelberger +3 more
wiley +1 more source
Model for tumour growth with treatment by continuous and pulsed chemotherapy [PDF]
, 2013 Peer ...
A.M. Batista +29 more
core +2 more sources
A Transcriptomic Analysis of Cancer‐Stromal Interactome in Lung Cancer Xenograft Models
Cancer Science, EarlyView.We conducted a comprehensive analysis of the lung cancer interactome to identify key ligand–receptor pairs involved in the aggressiveness of lung adenocarcinoma. Tumor necrosis factor superfamily member 12 and its receptor tumor necrosis factor receptor superfamily member 12A signaling axis may be potential candidates for therapeutic intervention for ...
Yuriko Takayama‐Isagawa +16 more
wiley +1 more source
Research in Pharmaceutical Sciences, 2017 Mono-targeting by imatinib as a main antitumor agent does not always accomplish complete cancer suppression. 2,5-dimethyl-celecoxib (DMC) is a close structural analog of the selective cyclooxygenase-2 (COX-2) inhibitor, celecoxib, that lacks COX-2 ...
Somayeh Atari-Hajipirloo +3 more
doaj +1 more source
Cancer Science, EarlyView.Mass spectrometry‐based phosphoproteomics for mechanistic dissection of cancer signaling pathways and uncovering therapeutic vulnerabilities. ABSTRACT Protein phosphorylation is a central post‐translational modification regulating cellular signaling, frequently dysregulated in cancer.
Hirokazu Shoji +2 more
wiley +1 more source
Therapeutic Advances in HematologyBackground: Generics imatinib became an alternative treatment option for chronic myeloid leukemia (CML) patients in China. However, clinicians and patients alike harbor concerns regarding the long-term safety of generic imatinib.
Fang Cheng +5 more
doaj +1 more source